FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to melanoma treatment. Disclosed is use of a composition containing a therapeutically effective amount of apilimod or a pharmaceutically acceptable salt thereof, for treating melanoma in a subject in combination with vemurafenib. Also disclosed is a method of identifying a human being having a melanoma patient for the purpose of treating using a combined therapy.
EFFECT: group of inventions provides a synergetic effect in treating melanoma.
9 cl, 4 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APILIMOD COMPOSITIONS AND METHODS OF USING THEM IN TREATING COLORECTAL CANCER | 2015 |
|
RU2739992C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| METHODS OF TREATING CANCER USING APILIMOD | 2016 |
|
RU2738934C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| IMPROVED THERAPEUTIC INDEX OF INHIBITORS AGAINST IMMUNE CHECKPOINT USING COMBINATION THERAPY INCLUDING PHY906 EXTRACT, SCUTELLARIA BAICALENSIS GEORGI (S) EXTRACT OR COMPOUND OF SUCH EXTRACTS | 2017 |
|
RU2753523C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| METHOD FOR REDUCING MULTI-DRUG RESISTANCE WITH USING INOSITOL TRIPYROPHOSPHATE | 2010 |
|
RU2563127C2 |
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS | 2016 |
|
RU2760835C2 |
| TREATING CANCER WITH IMMUNOSTIMULANTS | 2015 |
|
RU2740288C2 |
| PHARMACEUTICAL COMBINATIONS OF CDK4/6 INHIBITOR AND B-Raf INHIBITOR | 2013 |
|
RU2685250C2 |
